Articles related to DRUG SHORTAGES

ASHP urged HRSA in a June 2 letter to take immediate enforcement action against Eli Lilly after the manufacturer gave an initial group of 340B-covered entities five business days to submit detailed claims-level data or lose access to discounted pricing across its full drug portfolio, including in-house hospital pharmacy dispensing and medically administered products; as of mid-June, the threatened cutoffs had not yet taken effect for many affected entities.

Falling Medicaid enrollment under the One Big Beautiful Bill Act is eroding the disproportionate share hospital percentages that determine 340B Drug Pricing Program eligibility at safety-net hospitals, according to a presentation at HOPA 2026.

The introduction of lisdexamfetamine, a generic for Vyvanse, initially showed promise in increasing access to ADHD treatment. However, it too has fallen into shortage, highlighting the ongoing challenges in meeting patient demand.

The recent recall of Zenzedi 30 mg tablets due to contamination stresses the importance of meticulous medication management and awareness of the broader challenges in ADHD treatment availability and safety.

The stimulant crisis is affecting ADHD treatment across the board; Dr. Greg Mattingly offers crucial insights into navigating this challenging landscape. Learn about alternative treatment options to better serve your patients.

The DEA and FDA are addressing the current prescription stimulant shortage, emphasizing both the importance of patient access and the need for responsible prescribing. Stay informed on the latest updates and consider alternative treatments where appropriate.